Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo

(2015) Min Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

(2015) Nicholas David James et al.   EUROPEAN UROLOGY

A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors

(2015) Yi-Chao Zheng et al.   MEDICINAL RESEARCH REVIEWS

Integrated network model provides new insights into castration-resistant prostate cancer

(2015) Yanling Hu et al.   Scientific Reports

Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data

(2015) Thomas W. Flaig et al.   Cancer Medicine

Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma

(2014) Emily R Theisen et al.   BMC CANCER

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth

(2014) S. Sankar et al.   CLINICAL CANCER RESEARCH

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

(2014) W Fiskus et al.   LEUKEMIA

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Throughput Virtual Screening Identifies Novel N′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors

(2013) Venkataswamy Sorna et al.   JOURNAL OF MEDICINAL CHEMISTRY

Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1/2 and c-Myc

(2013) K. Hatano et al.   MOLECULAR CANCER RESEARCH

Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation

(2013) Lina Gao et al.   PLoS One

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

(2012) Josep Domingo-Domenech et al.   CANCER CELL

Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor

(2012) Dominica Willmann et al.   INTERNATIONAL JOURNAL OF CANCER

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients

(2011) André O von Bueren et al.   BMC CANCER

Novel Histone Demethylase LSD1 Inhibitors Selectively Target Cancer Cells with Pluripotent Stem Cell Properties

(2011) J. Wang et al.   CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function

(2011) Ching-Yuan Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

(2011) Amanda J O'Neill et al.   Molecular Cancer

LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells

(2011) Antonio Adamo et al.   NATURE CELL BIOLOGY

Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition

(2011) Oliver G McDonald et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells

(2010) Jung Jin Hwang et al.   JOURNAL OF UROLOGY

LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer

(2009) Yan Wang et al.   CELL

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

(2009) Qianben Wang et al.   CELL

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models

(2009) Claudio Festuccia et al.   ENDOCRINE-RELATED CANCER

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY